rTMS for Cannabis Use Disorder

N/A

Recruiting

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)

Awards & highlights

No Placebo-Only Group

Summary

This trial will explore brain-based approach (rTMS) to treat cannabis use disorder (CUD), to reduce craving and consumption and improve executive function. It could provide the first widely adopted clinical rTMS intervention for CUD.

Who is the study for?

This trial is for adults aged 18-65 with cannabis use disorder, using cannabis at least 5 days a week and aiming to reduce or quit. They must have a certain level of dependency and be on stable psychiatric meds if any. Excluded are pregnant individuals, those with severe mental health disorders, other primary substance abuse issues, seizure history, significant head injury, unstable medical conditions, or specific medications.

What is being tested?

The study tests repetitive transcranial magnetic stimulation (rTMS) using the MMC-140 coil on people with cannabis use disorder over four weeks. It will assess how well this non-invasive brain stimulation works in reducing cravings and consumption by exciting or inhibiting brain activity related to addiction.

What are the potential side effects?

While rTMS is generally considered safe, potential side effects include discomfort at the treatment site, headache, lightheadedness, tingling sensations during scalp application or muscle contractions under the treatment coil.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms) for reporting.